4 Biotech Stocks Moving on Buyout Buzz

SNY stock has recently benefited from a round of short covering

Jan 22, 2018 at 10:58 AM
facebook twitter linkedin


Juno Therapeutics Inc (NASDAQ:JUNO) agreed to be bought out by Celgene Corporation (NASDAQ:CELG), confirming last week's reports in the Wall Street Journal. CELG already owns a 9.7% stake in JUNO, but will purchase the remainder of the company in an all-cash deal valued at roughly $9 billion, or $87 per JUNO share -- allowing it access to the Seattle-based firm's CAR-T cancer drug pipeline.

At last check, JUNO stock was trading up 27% at $86.09 -- earlier topping out just shy of the purchase price, at $86.28. CELG stock, on the other hand, is trading down 1% at $101.62. This downside isn't anything new for Celgene shares, which have shed roughly 26% in the past six months, and recent resistance forming at the stock's 60-day trendline.

In spite of CELG's technical troubles, put options have rarely been cheaper compared to their call counterparts. The stock's 30-day implied volatility skew of -1.4% ranks below 99% of all comparable readings taken in the past year.

Sanofi Will Pay $11.6 Billion for Bioverativ

Another biotech buyout making waves today is Sanofi SA's (NYSE:SNY) $11.6 billion all-cash bid for Bioverativ Inc (NASDAQ:BIVV), which works out to $105 per BIVV shares. The purchase will add Bioverativ's hemophilia treatments to the French drugmaker's rare disease portfolio.

BIVV stock is up 62.1% at last check to trade at $103.94, hitting a high of $104.30 in early trading. SNY, meanwhile, has plunged 3.9% to trade at $42.86, bringing its three-month deficit to 13.7%. More recently, the security's rally off its late-December lows was swiftly rejected by Sanofi's 60-day moving average, a trendline that helped usher the shares higher from April through June of last year.

Part of Sanofi's recent rebound was likely fueled by short sellers, with short interest down 22.92% in the most recent reporting period. However, this source of buying power is nearly depleted, considering it would take a little more than one session to cover the remaining shorted SNY shares.

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners